LCZ696 (sacubitril/valsartan) for patients with heart failure

Adrian V. Hernandez, Vinay Pasupuleti, Maciej Banach, Agata M. Bielecka-Dabrowa

Research output: Contribution to journalArticlepeer-review

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.

Original languageEnglish
Article numberCD013517
JournalCochrane Database of Systematic Reviews
Volume2020
Issue number1
DOIs
StatePublished - 14 Jan 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'LCZ696 (sacubitril/valsartan) for patients with heart failure'. Together they form a unique fingerprint.

Cite this